AtriCure, Inc. (ATRC)

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio.

AtriCure (NASDAQ: ATRC) reported fourth-quarter and full-year 2025 results that management said reflected accelerating growth in several core franchises, improving profitability, and progress on major clinical and product development initiatives. The company also reaffirmed its 2026 outlook for 12% to 14% revenue growth. Full-year and fourth-quarter financial results For full-year 2025, AtriCure posted worldwide revenue of

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript

AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2025 and full year 2025 financial results. “Our 2025 performance reflects strong execution and continued momentum in our business. We delivered 15% revenue growth for the year and strengthened profitability while advancing key innovation and c.

AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) gapped down before the market opened on Wednesday after JPMorgan Chase and Co. downgraded the stock from an overweight rating to a neutral rating. The stock had previously closed at $37.86, but opened at $34.00. JPMorgan Chase and Co. now has a $36.00 price target on the stock.

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financi.

AtriCure tops a screen of high-efficiency stocks, joined by REV Group, Oceaneering International and Analog Devices after beating industry averages.

Summary HARBOR CAPITAL ADVISORS, INC. raised its stake in AtriCure Inc (ATRC) by 17.2%, purchasing 4,925 shares to own 33,564 shares valued at about $1

Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to

AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quar.

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year price objective